OPKO Health, Inc. (OPK) 10-Year Financial Performance & Capital Metrics

OPK • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesGeneral Clinical Laboratories

AboutOPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.Show more

Revenue $713M -17.4%
EBITDA -$54M -4.2%
Net Income -$53M +71.8%
EPS (Diluted) -0.08 +69.3%
Gross Margin 43.61% +18.4%
EBITDA Margin -7.56% -26.2%
Operating Margin -21.32% -17.3%
Net Margin -7.46% +65.9%
ROE -3.86% +69.8%
ROIC -7.46% -5.6%
Debt/Equity 0.37 +57.2%
Interest Coverage -3.20 +72.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 7.7% through buybacks
✓Trading at only 0.7x book value

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.85%

5Y-4.59%

3Y-26.21%

TTM-9.75%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM-39.58%

ROCE

10Y Avg-6.42%

5Y Avg-4.77%

3Y Avg-9.18%

Latest-7.96%

Peer Comparison

General Clinical Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
DGXQuest Diagnostics Incorporated	21.16B	190.26	24.74	6.7%	8.93%	13.14%	4.29%	1.03
OPKOPKO Health, Inc.	982.66M	1.28	-16.69	-17.41%	-21.93%	-10.79%		0.37
FLGTFulgent Genetics, Inc.	885.64M	28.65	-20.32	-1.99%	-13.62%	-3.84%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	491.7M	1.22B	966.01M	990.3M	901.93M	1.44B	1.77B	1B	863.5M	713.14M
Revenue Growth %	4.4%	1.48%	-0.21%	0.03%	-0.09%	0.59%	0.24%	-0.43%	-0.14%	-0.17%
Cost of Goods Sold+	235.24M	611.5M	620.13M	604.6M	572.48M	894.41M	1.19B	715.98M	545.37M	402.11M
COGS % of Revenue	0.48%	0.5%	0.64%	0.61%	0.63%	0.62%	0.67%	0.71%	0.63%	0.56%
Gross Profit+	256.5M	610.2M	345.88M	385.7M	329.45M	541M	581.52M	288.22M	318.13M	311.03M
Gross Margin %	0.52%	0.5%	0.36%	0.39%	0.37%	0.38%	0.33%	0.29%	0.37%	0.44%
Gross Profit Growth %	4.95%	1.38%	-0.43%	0.12%	-0.15%	0.64%	0.07%	-0.5%	0.1%	-0.02%
Operating Expenses+	354.98M	602.56M	625.74M	551.9M	603.5M	483.29M	562.77M	514.47M	475.15M	463.1M
OpEx % of Revenue	0.72%	0.49%	0.65%	0.56%	0.67%	0.34%	0.32%	0.51%	0.55%	0.65%
Selling, General & Admin	196.58M	490.9M	414.63M	358.4M	343.31M	355.57M	468.86M	372.67M	300.56M	304.22M
SG&A % of Revenue	0.4%	0.4%	0.43%	0.36%	0.38%	0.25%	0.26%	0.37%	0.35%	0.43%
Research & Development	99.49M	113.87M	126.44M	135.69M	117.87M	75.32M	76.85M	73.89M	89.59M	105.21M
R&D % of Revenue	0.2%	0.09%	0.13%	0.14%	0.13%	0.05%	0.04%	0.07%	0.1%	0.15%
Other Operating Expenses	58.92M	0	81.25M	72.89M	142.33M	52.4M	17.07M	67.91M	85M	53.66M
Operating Income+	-98.48M	-73.28M	-276.44M	-171.2M	-274.05M	57.71M	18.75M	-226.25M	-157.02M	-152.06M
Operating Margin %	-0.2%	-0.06%	-0.29%	-0.17%	-0.3%	0.04%	0.01%	-0.23%	-0.18%	-0.21%
Operating Income Growth %	0.32%	0.26%	-2.77%	0.38%	-0.6%	1.21%	-0.68%	-13.07%	0.31%	0.03%
EBITDA+	-56.23M	23.3M	-174.35M	-73.85M	-180.25M	143.08M	97.47M	-117.6M	-51.72M	-53.89M
EBITDA Margin %	-0.11%	0.02%	-0.18%	-0.07%	-0.2%	0.1%	0.05%	-0.12%	-0.06%	-0.08%
EBITDA Growth %	0.57%	1.41%	-8.48%	0.58%	-1.44%	1.79%	-0.32%	-2.21%	0.56%	-0.04%
D&A (Non-Cash Add-back)	42.25M	96.58M	102.09M	97.34M	93.81M	85.36M	78.72M	108.66M	105.3M	98.18M
EBIT	-129.58M	-89.39M	-265.32M	-165.38M	-283.45M	70.62M	4.86M	-379.46M	-170.81M	37.1M
Net Interest Income+	-8.16M	-6.95M	-5.99M	-10.65M	-19.81M	-21.78M	-18.85M	-10.07M	-9.52M	-39.04M
Interest Income	255K	478K	610K	1.24M	1.71M	152K	28K	1.98M	3.98M	8.43M
Interest Expense	8.42M	7.43M	6.6M	11.89M	21.52M	21.93M	18.88M	12.06M	13.51M	47.47M
Other Income/Expense	-39.52M	-271K	4.52M	-6.07M	-30.91M	-9.51M	-33.4M	-165.65M	-27.41M	141.7M
Pretax Income+	-138M	-73.5M	-271.92M	-177.27M	-304.96M	48.2M	-14.65M	-391.9M	-184.43M	-10.36M
Pretax Margin %	-0.28%	-0.06%	-0.28%	-0.18%	-0.34%	0.03%	-0.01%	-0.39%	-0.21%	-0.01%
Income Tax+	-113.67M	-56.1M	18.86M	-38.7M	7.06M	17.62M	15.49M	-63.5M	4.44M	42.84M
Effective Tax Rate %	0.22%	0.66%	1.12%	0.86%	1.03%	0.63%	2.06%	0.84%	1.02%	5.14%
Net Income+	-30.03M	-48.36M	-305.25M	-153.04M	-314.93M	30.59M	-30.14M	-328.4M	-188.86M	-53.22M
Net Margin %	-0.06%	-0.04%	-0.32%	-0.15%	-0.35%	0.02%	-0.02%	-0.33%	-0.22%	-0.07%
Net Income Growth %	0.83%	-0.61%	-5.31%	0.5%	-1.06%	1.1%	-1.99%	-9.89%	0.42%	0.72%
Net Income (Continuing)	-31.43M	-17.43M	-305.25M	-153.04M	-314.93M	30.59M	-30.14M	-328.4M	-188.86M	-53.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.06	-0.05	-0.55	-0.27	-0.53	0.05	-0.05	-0.46	-0.25	-0.08
EPS Growth %	0.85%	0.17%	-10%	0.51%	-0.96%	1.09%	-1.95%	-9.11%	0.46%	0.69%
EPS (Basic)	-0.06	-0.05	-0.55	-0.27	-0.53	0.05	-0.05	-0.46	-0.25	-0.08
Diluted Shares Outstanding	500M	502M	559.16M	566.67M	595.45M	640.65M	648.08M	719.06M	751.77M	694.02M
Basic Shares Outstanding	500M	507.83M	555M	563.14M	595.45M	640.65M	648.08M	719.06M	751.77M	694.02M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	454.1M	483.6M	348.86M	317.7M	324.05M	523.18M	823.01M	394.52M	309.48M	662.09M
Cash & Short-Term Investments	193.6M	168.7M	91.5M	96.5M	85.45M	72.21M	134.71M	153.19M	95.88M	431.94M
Cash Only	193.6M	168.73M	91.5M	96.47M	85.45M	72.21M	134.71M	153.19M	95.88M	431.94M
Short-Term Investments	0	-33K	0	27K	0	0	0	0	0	0
Accounts Receivable	208.9M	249.49M	187.05M	161.98M	157.69M	302.26M	265.59M	148.61M	130.2M	152.05M
Days Sales Outstanding	155.07	74.54	70.68	59.7	63.81	76.86	54.62	54.02	55.04	77.82
Inventory	39.68M	47.23M	49.33M	42.3M	53.43M	132.34M	86.5M	74.06M	65.7M	56.8M
Days Inventory Outstanding	61.57	28.19	29.04	25.54	34.07	54.01	26.46	37.76	43.97	51.56
Other Current Assets	903K	7.51M	9.24M	3.85M	15.84M	5.31M	321.19M	6.25M	7.67M	10.71M
Total Non-Current Assets+	2.35B	2.28B	2.24B	2.13B	1.99B	1.95B	1.58B	1.77B	1.7B	1.54B
Property, Plant & Equipment	131.8M	122.83M	146.56M	144.67M	166.49M	178.29M	123.95M	121.6M	143.52M	124.14M
Fixed Asset Turnover	3.73x	9.95x	6.59x	6.85x	5.42x	8.05x	14.32x	8.26x	6.02x	5.74x
Goodwill	743.35M	704.6M	717.1M	700.19M	671.94M	680.6M	520.6M	595.85M	598.26M	529.25M
Intangible Assets	1.43B	1.41B	1.33B	1.25B	1.12B	1.07B	911.88M	1.02B	935.28M	811.61M
Long-Term Investments	34.72M	41.14M	40.64M	31.23M	20.75M	15.73M	10.71M	28.05M	16.08M	54.58M
Other Non-Current Assets	809.9M	933.7M	5.62M	797.6M	6.89M	10.06M	9.55M	8.71M	9.08M	18.54M
Total Assets+	2.8B	2.77B	2.59B	2.45B	2.31B	2.47B	2.4B	2.17B	2.01B	2.2B
Asset Turnover	0.18x	0.44x	0.37x	0.40x	0.39x	0.58x	0.74x	0.46x	0.43x	0.32x
Asset Growth %	1.21%	-0.01%	-0.06%	-0.05%	-0.06%	0.07%	-0.03%	-0.1%	-0.07%	0.09%
Total Current Liabilities+	251.9M	263.3M	312.03M	256.8M	249.12M	375.48M	330.01M	213.48M	200.05M	193.1M
Accounts Payable	72.53M	53.36M	74.31M	47.4M	62.54M	100.88M	82.04M	66.99M	69.68M	47.07M
Days Payables Outstanding	112.55	31.85	43.74	28.61	39.87	41.17	25.1	34.15	46.63	42.73
Short-Term Debt	11.47M	11.98M	11.93M	37.41M	24.4M	36.18M	14.69M	36.59M	27.29M	15.02M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	258K	0	0	0
Other Current Liabilities	54.92M	73.27M	110.53M	87.88M	109.31M	179.33M	74.09M	40.24M	56.92M	41.09M
Current Ratio	1.80x	1.84x	1.12x	1.24x	1.30x	1.39x	2.49x	1.85x	1.55x	3.43x
Quick Ratio	1.65x	1.66x	0.96x	1.07x	1.09x	1.04x	2.23x	1.50x	1.22x	3.13x
Cash Conversion Cycle	104.09	70.88	55.98	56.63	58.01	89.7	55.99	57.62	52.37	86.65
Total Non-Current Liabilities+	567.9M	411.5M	434.3M	403M	445.39M	426.03M	384.58M	392.13M	422.43M	641.67M
Long-Term Debt	123.62M	83.23M	134.88M	167.15M	259.86M	225.83M	190.16M	219.47M	222.03M	422.18M
Capital Lease Obligations	9.29M	7.22M	7.79M	5.62M	31.71M	32.56M	36.02M	35.05M	61.41M	52.91M
Deferred Tax Liabilities	226M	165.3M	148.73M	115.2M	118.72M	137.21M	148.49M	126.43M	126.77M	140.8M
Other Non-Current Liabilities	45.92M	66.72M	83.92M	55.93M	35.1M	30.43M	9.71M	11.05M	12.2M	25.77M
Total Liabilities	819.8M	674.8M	746.33M	659.8M	694.51M	801.51M	714.59M	605.61M	622.48M	834.76M
Total Debt+	149.74M	105.45M	157.99M	31.6M	315.97M	294.57M	254.75M	305.55M	326.56M	504.44M
Net Debt	-43.86M	-63.28M	66.49M	-64.87M	230.52M	222.36M	120.05M	152.36M	230.68M	72.51M
Debt / Equity	0.08x	0.05x	0.09x	0.02x	0.20x	0.18x	0.15x	0.20x	0.24x	0.37x
Debt / EBITDA	-	4.53x	-	-	-	2.06x	2.61x	-	-	-
Net Debt / EBITDA	-	-2.72x	-	-	-	1.55x	1.23x	-	-	-
Interest Coverage	-11.70x	-9.86x	-41.88x	-14.40x	-12.74x	2.63x	0.99x	-18.77x	-11.63x	-3.20x
Total Equity+	1.98B	2.09B	1.84B	1.79B	1.61B	1.67B	1.69B	1.56B	1.39B	1.37B
Equity Growth %	1.39%	0.06%	-0.12%	-0.03%	-0.1%	0.04%	0.01%	-0.07%	-0.11%	-0.02%
Book Value per Share	3.96	4.17	3.30	3.16	2.71	2.61	2.60	2.17	1.85	1.97
Total Shareholders' Equity	1.98B	2.09B	1.84B	1.79B	1.61B	1.67B	1.69B	1.56B	1.39B	1.37B
Common Stock	5.46M	5.59M	5.6M	5.87M	6.7M	6.71M	6.9M	7.81M	7.82M	7.01M
Retained Earnings	-704.87M	-729.95M	-1.05B	-1.2B	-1.51B	-1.48B	-1.51B	-1.82B	-2.01B	-2.07B
Treasury Stock	-3.65M	-1.91M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M
Accumulated OCI	-22.54M	-27.01M	-528K	-20.13M	-22.07M	-4.22M	-30.5M	-43.32M	-38.03M	-56.13M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	164.02M	32.05M	-92.08M	-109.14M	-172.52M	39.48M	38.34M	-95.19M	-28.2M	-183.49M
Operating CF Margin %	0.33%	0.03%	-0.1%	-0.11%	-0.19%	0.03%	0.02%	-0.09%	-0.03%	-0.26%
Operating CF Growth %	2.81%	-0.8%	-3.87%	-0.19%	-0.58%	1.23%	-0.03%	-3.48%	0.7%	-5.51%
Net Income	-31.43M	-25.08M	-305.25M	-153.04M	-314.93M	30.59M	-30.14M	-328.4M	-188.86M	-53.22M
Depreciation & Amortization	42.25M	96.58M	102.09M	97.34M	93.81M	85.36M	78.72M	108.66M	105.3M	98.18M
Stock-Based Compensation	26.07M	42.69M	28.31M	21.76M	13.42M	8.95M	13.63M	18.51M	11.41M	11.05M
Deferred Taxes	-123.54M	-66.3M	16.09M	-35.13M	4.32M	15.64M	10.16M	-74.41M	146K	14.74M
Other Non-Cash Items	70.6M	27.37M	18.33M	18.07M	99.66M	-3.45M	-13.54M	137.8M	22.01M	-286.41M
Working Capital Changes	180.06M	-43.21M	48.35M	-58.14M	-68.81M	-97.61M	-20.48M	42.65M	21.8M	32.17M
Change in Receivables	-29.39M	-25.64M	58.01M	20.4M	7.38M	-150.44M	5.23M	128.6M	3.41M	-220K
Change in Inventory	-5.88M	-6.61M	-3.54M	4.59M	-12.13M	-77.64M	30.68M	13.66M	15.2M	4.22M
Change in Payables	-18.12M	-19.82M	20.17M	-26.08M	15.64M	37.16M	-10.85M	-9.39M	2.83M	-20.66M
Cash from Investing+	-99.22M	-20.7M	-46.67M	-26.12M	-13.27M	-18.33M	35.95M	91.04M	-18.2M	352.21M
Capital Expenditures	-15.85M	-23.55M	-46.52M	-27.86M	-12.74M	-33.68M	-32.16M	-24.58M	-16.27M	-25.01M
CapEx % of Revenue	0.03%	0.02%	0.05%	0.03%	0.01%	0.02%	0.02%	0.02%	0.02%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-9.38M	1.4M	-39.25M	-26.64M	671K	245K	66.03M	1.95M	2.71M	210.62M
Cash from Financing+	33.01M	-35.2M	61.04M	140.91M	175.25M	-35.08M	-10.35M	22.97M	-11.3M	184.17M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	26.02M	8.58M	2.13M	1.17M	-7.76M	756K	893K	-774K	-272K	-13.59M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	148.18M	8.5M	-138.6M	-137M	-185.26M	5.79M	6.18M	-119.77M	-44.47M	-208.5M
FCF Margin %	0.3%	0.01%	-0.14%	-0.14%	-0.21%	0%	0%	-0.12%	-0.05%	-0.29%
FCF Growth %	2.56%	-0.94%	-17.31%	0.01%	-0.35%	1.03%	0.07%	-20.38%	0.63%	-3.69%
FCF per Share	0.30	0.02	-0.25	-0.24	-0.31	0.01	0.01	-0.17	-0.06	-0.30
FCF Conversion (FCF/Net Income)	-5.46x	-0.66x	0.30x	0.71x	0.55x	1.29x	-1.27x	0.29x	0.15x	3.45x
Interest Paid	4.57M	2.89M	1.31M	0	11.87M	10.91M	8.52M	7.42M	8.13M	20.88M
Taxes Paid	4.88M	27.12M	5.42M	0	2.67M	903K	5.97M	8.04M	3.71M	10.01M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2.14%	-2.38%	-15.51%	-8.42%	-18.49%	1.86%	-1.8%	-20.23%	-12.8%	-3.86%
Return on Invested Capital (ROIC)	-5.28%	-2.77%	-10.53%	-7.06%	-11.51%	2.32%	0.76%	-9.64%	-7.06%	-7.46%
Gross Margin	52.17%	49.95%	35.8%	38.95%	36.53%	37.69%	32.77%	28.7%	36.84%	43.61%
Net Margin	-6.11%	-3.96%	-31.6%	-15.45%	-34.92%	2.13%	-1.7%	-32.7%	-21.87%	-7.46%
Debt / Equity	0.08x	0.05x	0.09x	0.02x	0.20x	0.18x	0.15x	0.20x	0.24x	0.37x
Interest Coverage	-11.70x	-9.86x	-41.88x	-14.40x	-12.74x	2.63x	0.99x	-18.77x	-11.63x	-3.20x
FCF Conversion	-5.46x	-0.66x	0.30x	0.71x	0.55x	1.29x	-1.27x	0.29x	0.15x	3.45x
Revenue Growth	439.74%	148.46%	-20.93%	2.51%	-8.92%	59.15%	23.64%	-43.42%	-14.01%	-17.41%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Service	-	-	-	813.25M	716.43M	1.26B	1.61B	755.63M	515.27M	480.67M
Service Growth	-	-	-	-	-11.90%	76.18%	27.32%	-52.98%	-31.81%	-6.72%
Product	-	-	-	107.11M	-	119.95M	141.77M	142.84M	167.56M	155.11M
Product Growth	-	-	-	-	-	-	18.19%	0.76%	17.30%	-7.43%
Transfer of Intellectual Property and Other	-	-	-	-	-	-	25.84M	105.72M	180.66M	77.36M
Transfer of Intellectual Property and Other Growth	-	-	-	-	-	-	-	309.11%	70.89%	-57.18%
Client Payers	-	-	-	150.26M	159.97M	637.64M	-	-	-	-
Client Payers Growth	-	-	-	-	6.46%	298.60%	-	-	-	-
Health Insurers	-	-	-	370.1M	419.1M	483.64M	-	-	-	-
Health Insurers Growth	-	-	-	-	13.24%	15.40%	-	-	-	-
Government Payers	-	-	-	271.59M	116.66M	90.29M	-	-	-	-
Government Payers Growth	-	-	-	-	-57.04%	-22.61%	-	-	-	-
Rayaldee	-	1.6M	21.58M	36.72M	-	88.19M	-	-	-	-
Rayaldee Growth	-	-	1248.88%	70.12%	-	-	-	-	-	-
Patients	-	-	-	21.3M	20.7M	50.67M	-	-	-	-
Patients Growth	-	-	-	-	-2.84%	144.78%	-	-	-	-
Transfer Of Intellectual Property And Other	-	-	-	69.91M	-	28.7M	-	-	-	-
Transfer Of Intellectual Property And Other Growth	-	-	-	-	-	-	-	-	-	-
Diagnostics	329.6M	-	-	-	-	-	-	-	-	-
Diagnostics Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	344.46M	1.01B	908.97M	837.51M	751.1M	1.32B	1.64B	783.21M	597.82M	546.3M
UNITED STATES Growth	-	194.48%	-10.39%	-7.86%	-10.32%	75.45%	24.48%	-52.25%	-23.67%	-8.62%
CHILE	29.89M	35.36M	44.29M	41.22M	33.64M	44.15M	63.8M	62.04M	68.49M	65.05M
CHILE Growth	-	18.33%	25.23%	-6.93%	-18.38%	31.24%	44.49%	-2.75%	10.39%	-5.03%
IRELAND	78.99M	137.78M	77.28M	78.1M	81.17M	43.92M	32.81M	117.21M	141.47M	48.4M
IRELAND Growth	-	74.44%	-43.91%	1.06%	3.93%	-45.89%	-25.30%	257.26%	20.69%	-65.79%
SPAIN	16.62M	15.81M	18.29M	18.2M	18.75M	16.93M	22.68M	22.48M	23.52M	24.63M
SPAIN Growth	-	-4.87%	15.64%	-0.49%	3.03%	-9.68%	33.96%	-0.90%	4.63%	4.75%
MEXICO	3.67M	2.99M	4.61M	5.6M	8.03M	7.87M	11.01M	14.55M	20.22M	23.87M
MEXICO Growth	-	-18.61%	54.12%	21.56%	43.48%	-2.08%	39.92%	32.18%	38.98%	18.06%
Other Countries	-	6K	120K	167K	476K	526K	507K	863K	2.25M	3.12M
Other Countries Growth	-	-	1900.00%	39.17%	185.03%	10.50%	-3.61%	70.22%	160.25%	39.05%
ISRAEL	18.11M	15.32M	13.95M	9.48M	8.77M	4.25M	3.56M	3.85M	9.74M	1.77M
ISRAEL Growth	-	-15.41%	-8.92%	-32.06%	-7.49%	-51.52%	-16.18%	7.91%	153.26%	-81.80%

Frequently Asked Questions

Growth & Financials

OPKO Health, Inc. (OPK) reported $642.1M in revenue for fiscal year 2024. This represents a 2195% increase from $28.0M in 2011.

OPKO Health, Inc. (OPK) saw revenue decline by 17.4% over the past year.

OPKO Health, Inc. (OPK) reported a net loss of $140.8M for fiscal year 2024.

Dividend & Returns

OPKO Health, Inc. (OPK) has a return on equity (ROE) of -3.9%. Negative ROE indicates the company is unprofitable.

OPKO Health, Inc. (OPK) had negative free cash flow of $212.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

OPKO Health, Inc. (OPK) 10-Year Financial Performance & Capital Metrics

OPK • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesGeneral Clinical Laboratories

Revenue $713M -17.4%
EBITDA -$54M -4.2%
Net Income -$53M +71.8%
EPS (Diluted) -0.08 +69.3%
Gross Margin 43.61% +18.4%
EBITDA Margin -7.56% -26.2%
Operating Margin -21.32% -17.3%
Net Margin -7.46% +65.9%
ROE -3.86% +69.8%
ROIC -7.46% -5.6%
Debt/Equity 0.37 +57.2%
Interest Coverage -3.20 +72.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 7.7% through buybacks
✓Trading at only 0.7x book value

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.85%

5Y-4.59%

3Y-26.21%

TTM-9.75%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM-39.58%

ROCE

10Y Avg-6.42%

5Y Avg-4.77%

3Y Avg-9.18%

Latest-7.96%

Peer Comparison

General Clinical Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
DGXQuest Diagnostics Incorporated	21.16B	190.26	24.74	6.7%	8.93%	13.14%	4.29%	1.03
OPKOPKO Health, Inc.	982.66M	1.28	-16.69	-17.41%	-21.93%	-10.79%		0.37
FLGTFulgent Genetics, Inc.	885.64M	28.65	-20.32	-1.99%	-13.62%	-3.84%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	491.7M	1.22B	966.01M	990.3M	901.93M	1.44B	1.77B	1B	863.5M	713.14M
Revenue Growth %	4.4%	1.48%	-0.21%	0.03%	-0.09%	0.59%	0.24%	-0.43%	-0.14%	-0.17%
Cost of Goods Sold+	235.24M	611.5M	620.13M	604.6M	572.48M	894.41M	1.19B	715.98M	545.37M	402.11M
COGS % of Revenue	0.48%	0.5%	0.64%	0.61%	0.63%	0.62%	0.67%	0.71%	0.63%	0.56%
Gross Profit+	256.5M	610.2M	345.88M	385.7M	329.45M	541M	581.52M	288.22M	318.13M	311.03M
Gross Margin %	0.52%	0.5%	0.36%	0.39%	0.37%	0.38%	0.33%	0.29%	0.37%	0.44%
Gross Profit Growth %	4.95%	1.38%	-0.43%	0.12%	-0.15%	0.64%	0.07%	-0.5%	0.1%	-0.02%
Operating Expenses+	354.98M	602.56M	625.74M	551.9M	603.5M	483.29M	562.77M	514.47M	475.15M	463.1M
OpEx % of Revenue	0.72%	0.49%	0.65%	0.56%	0.67%	0.34%	0.32%	0.51%	0.55%	0.65%
Selling, General & Admin	196.58M	490.9M	414.63M	358.4M	343.31M	355.57M	468.86M	372.67M	300.56M	304.22M
SG&A % of Revenue	0.4%	0.4%	0.43%	0.36%	0.38%	0.25%	0.26%	0.37%	0.35%	0.43%
Research & Development	99.49M	113.87M	126.44M	135.69M	117.87M	75.32M	76.85M	73.89M	89.59M	105.21M
R&D % of Revenue	0.2%	0.09%	0.13%	0.14%	0.13%	0.05%	0.04%	0.07%	0.1%	0.15%
Other Operating Expenses	58.92M	0	81.25M	72.89M	142.33M	52.4M	17.07M	67.91M	85M	53.66M
Operating Income+	-98.48M	-73.28M	-276.44M	-171.2M	-274.05M	57.71M	18.75M	-226.25M	-157.02M	-152.06M
Operating Margin %	-0.2%	-0.06%	-0.29%	-0.17%	-0.3%	0.04%	0.01%	-0.23%	-0.18%	-0.21%
Operating Income Growth %	0.32%	0.26%	-2.77%	0.38%	-0.6%	1.21%	-0.68%	-13.07%	0.31%	0.03%
EBITDA+	-56.23M	23.3M	-174.35M	-73.85M	-180.25M	143.08M	97.47M	-117.6M	-51.72M	-53.89M
EBITDA Margin %	-0.11%	0.02%	-0.18%	-0.07%	-0.2%	0.1%	0.05%	-0.12%	-0.06%	-0.08%
EBITDA Growth %	0.57%	1.41%	-8.48%	0.58%	-1.44%	1.79%	-0.32%	-2.21%	0.56%	-0.04%
D&A (Non-Cash Add-back)	42.25M	96.58M	102.09M	97.34M	93.81M	85.36M	78.72M	108.66M	105.3M	98.18M
EBIT	-129.58M	-89.39M	-265.32M	-165.38M	-283.45M	70.62M	4.86M	-379.46M	-170.81M	37.1M
Net Interest Income+	-8.16M	-6.95M	-5.99M	-10.65M	-19.81M	-21.78M	-18.85M	-10.07M	-9.52M	-39.04M
Interest Income	255K	478K	610K	1.24M	1.71M	152K	28K	1.98M	3.98M	8.43M
Interest Expense	8.42M	7.43M	6.6M	11.89M	21.52M	21.93M	18.88M	12.06M	13.51M	47.47M
Other Income/Expense	-39.52M	-271K	4.52M	-6.07M	-30.91M	-9.51M	-33.4M	-165.65M	-27.41M	141.7M
Pretax Income+	-138M	-73.5M	-271.92M	-177.27M	-304.96M	48.2M	-14.65M	-391.9M	-184.43M	-10.36M
Pretax Margin %	-0.28%	-0.06%	-0.28%	-0.18%	-0.34%	0.03%	-0.01%	-0.39%	-0.21%	-0.01%
Income Tax+	-113.67M	-56.1M	18.86M	-38.7M	7.06M	17.62M	15.49M	-63.5M	4.44M	42.84M
Effective Tax Rate %	0.22%	0.66%	1.12%	0.86%	1.03%	0.63%	2.06%	0.84%	1.02%	5.14%
Net Income+	-30.03M	-48.36M	-305.25M	-153.04M	-314.93M	30.59M	-30.14M	-328.4M	-188.86M	-53.22M
Net Margin %	-0.06%	-0.04%	-0.32%	-0.15%	-0.35%	0.02%	-0.02%	-0.33%	-0.22%	-0.07%
Net Income Growth %	0.83%	-0.61%	-5.31%	0.5%	-1.06%	1.1%	-1.99%	-9.89%	0.42%	0.72%
Net Income (Continuing)	-31.43M	-17.43M	-305.25M	-153.04M	-314.93M	30.59M	-30.14M	-328.4M	-188.86M	-53.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.06	-0.05	-0.55	-0.27	-0.53	0.05	-0.05	-0.46	-0.25	-0.08
EPS Growth %	0.85%	0.17%	-10%	0.51%	-0.96%	1.09%	-1.95%	-9.11%	0.46%	0.69%
EPS (Basic)	-0.06	-0.05	-0.55	-0.27	-0.53	0.05	-0.05	-0.46	-0.25	-0.08
Diluted Shares Outstanding	500M	502M	559.16M	566.67M	595.45M	640.65M	648.08M	719.06M	751.77M	694.02M
Basic Shares Outstanding	500M	507.83M	555M	563.14M	595.45M	640.65M	648.08M	719.06M	751.77M	694.02M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	454.1M	483.6M	348.86M	317.7M	324.05M	523.18M	823.01M	394.52M	309.48M	662.09M
Cash & Short-Term Investments	193.6M	168.7M	91.5M	96.5M	85.45M	72.21M	134.71M	153.19M	95.88M	431.94M
Cash Only	193.6M	168.73M	91.5M	96.47M	85.45M	72.21M	134.71M	153.19M	95.88M	431.94M
Short-Term Investments	0	-33K	0	27K	0	0	0	0	0	0
Accounts Receivable	208.9M	249.49M	187.05M	161.98M	157.69M	302.26M	265.59M	148.61M	130.2M	152.05M
Days Sales Outstanding	155.07	74.54	70.68	59.7	63.81	76.86	54.62	54.02	55.04	77.82
Inventory	39.68M	47.23M	49.33M	42.3M	53.43M	132.34M	86.5M	74.06M	65.7M	56.8M
Days Inventory Outstanding	61.57	28.19	29.04	25.54	34.07	54.01	26.46	37.76	43.97	51.56
Other Current Assets	903K	7.51M	9.24M	3.85M	15.84M	5.31M	321.19M	6.25M	7.67M	10.71M
Total Non-Current Assets+	2.35B	2.28B	2.24B	2.13B	1.99B	1.95B	1.58B	1.77B	1.7B	1.54B
Property, Plant & Equipment	131.8M	122.83M	146.56M	144.67M	166.49M	178.29M	123.95M	121.6M	143.52M	124.14M
Fixed Asset Turnover	3.73x	9.95x	6.59x	6.85x	5.42x	8.05x	14.32x	8.26x	6.02x	5.74x
Goodwill	743.35M	704.6M	717.1M	700.19M	671.94M	680.6M	520.6M	595.85M	598.26M	529.25M
Intangible Assets	1.43B	1.41B	1.33B	1.25B	1.12B	1.07B	911.88M	1.02B	935.28M	811.61M
Long-Term Investments	34.72M	41.14M	40.64M	31.23M	20.75M	15.73M	10.71M	28.05M	16.08M	54.58M
Other Non-Current Assets	809.9M	933.7M	5.62M	797.6M	6.89M	10.06M	9.55M	8.71M	9.08M	18.54M
Total Assets+	2.8B	2.77B	2.59B	2.45B	2.31B	2.47B	2.4B	2.17B	2.01B	2.2B
Asset Turnover	0.18x	0.44x	0.37x	0.40x	0.39x	0.58x	0.74x	0.46x	0.43x	0.32x
Asset Growth %	1.21%	-0.01%	-0.06%	-0.05%	-0.06%	0.07%	-0.03%	-0.1%	-0.07%	0.09%
Total Current Liabilities+	251.9M	263.3M	312.03M	256.8M	249.12M	375.48M	330.01M	213.48M	200.05M	193.1M
Accounts Payable	72.53M	53.36M	74.31M	47.4M	62.54M	100.88M	82.04M	66.99M	69.68M	47.07M
Days Payables Outstanding	112.55	31.85	43.74	28.61	39.87	41.17	25.1	34.15	46.63	42.73
Short-Term Debt	11.47M	11.98M	11.93M	37.41M	24.4M	36.18M	14.69M	36.59M	27.29M	15.02M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	258K	0	0	0
Other Current Liabilities	54.92M	73.27M	110.53M	87.88M	109.31M	179.33M	74.09M	40.24M	56.92M	41.09M
Current Ratio	1.80x	1.84x	1.12x	1.24x	1.30x	1.39x	2.49x	1.85x	1.55x	3.43x
Quick Ratio	1.65x	1.66x	0.96x	1.07x	1.09x	1.04x	2.23x	1.50x	1.22x	3.13x
Cash Conversion Cycle	104.09	70.88	55.98	56.63	58.01	89.7	55.99	57.62	52.37	86.65
Total Non-Current Liabilities+	567.9M	411.5M	434.3M	403M	445.39M	426.03M	384.58M	392.13M	422.43M	641.67M
Long-Term Debt	123.62M	83.23M	134.88M	167.15M	259.86M	225.83M	190.16M	219.47M	222.03M	422.18M
Capital Lease Obligations	9.29M	7.22M	7.79M	5.62M	31.71M	32.56M	36.02M	35.05M	61.41M	52.91M
Deferred Tax Liabilities	226M	165.3M	148.73M	115.2M	118.72M	137.21M	148.49M	126.43M	126.77M	140.8M
Other Non-Current Liabilities	45.92M	66.72M	83.92M	55.93M	35.1M	30.43M	9.71M	11.05M	12.2M	25.77M
Total Liabilities	819.8M	674.8M	746.33M	659.8M	694.51M	801.51M	714.59M	605.61M	622.48M	834.76M
Total Debt+	149.74M	105.45M	157.99M	31.6M	315.97M	294.57M	254.75M	305.55M	326.56M	504.44M
Net Debt	-43.86M	-63.28M	66.49M	-64.87M	230.52M	222.36M	120.05M	152.36M	230.68M	72.51M
Debt / Equity	0.08x	0.05x	0.09x	0.02x	0.20x	0.18x	0.15x	0.20x	0.24x	0.37x
Debt / EBITDA	-	4.53x	-	-	-	2.06x	2.61x	-	-	-
Net Debt / EBITDA	-	-2.72x	-	-	-	1.55x	1.23x	-	-	-
Interest Coverage	-11.70x	-9.86x	-41.88x	-14.40x	-12.74x	2.63x	0.99x	-18.77x	-11.63x	-3.20x
Total Equity+	1.98B	2.09B	1.84B	1.79B	1.61B	1.67B	1.69B	1.56B	1.39B	1.37B
Equity Growth %	1.39%	0.06%	-0.12%	-0.03%	-0.1%	0.04%	0.01%	-0.07%	-0.11%	-0.02%
Book Value per Share	3.96	4.17	3.30	3.16	2.71	2.61	2.60	2.17	1.85	1.97
Total Shareholders' Equity	1.98B	2.09B	1.84B	1.79B	1.61B	1.67B	1.69B	1.56B	1.39B	1.37B
Common Stock	5.46M	5.59M	5.6M	5.87M	6.7M	6.71M	6.9M	7.81M	7.82M	7.01M
Retained Earnings	-704.87M	-729.95M	-1.05B	-1.2B	-1.51B	-1.48B	-1.51B	-1.82B	-2.01B	-2.07B
Treasury Stock	-3.65M	-1.91M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M	-1.79M
Accumulated OCI	-22.54M	-27.01M	-528K	-20.13M	-22.07M	-4.22M	-30.5M	-43.32M	-38.03M	-56.13M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	164.02M	32.05M	-92.08M	-109.14M	-172.52M	39.48M	38.34M	-95.19M	-28.2M	-183.49M
Operating CF Margin %	0.33%	0.03%	-0.1%	-0.11%	-0.19%	0.03%	0.02%	-0.09%	-0.03%	-0.26%
Operating CF Growth %	2.81%	-0.8%	-3.87%	-0.19%	-0.58%	1.23%	-0.03%	-3.48%	0.7%	-5.51%
Net Income	-31.43M	-25.08M	-305.25M	-153.04M	-314.93M	30.59M	-30.14M	-328.4M	-188.86M	-53.22M
Depreciation & Amortization	42.25M	96.58M	102.09M	97.34M	93.81M	85.36M	78.72M	108.66M	105.3M	98.18M
Stock-Based Compensation	26.07M	42.69M	28.31M	21.76M	13.42M	8.95M	13.63M	18.51M	11.41M	11.05M
Deferred Taxes	-123.54M	-66.3M	16.09M	-35.13M	4.32M	15.64M	10.16M	-74.41M	146K	14.74M
Other Non-Cash Items	70.6M	27.37M	18.33M	18.07M	99.66M	-3.45M	-13.54M	137.8M	22.01M	-286.41M
Working Capital Changes	180.06M	-43.21M	48.35M	-58.14M	-68.81M	-97.61M	-20.48M	42.65M	21.8M	32.17M
Change in Receivables	-29.39M	-25.64M	58.01M	20.4M	7.38M	-150.44M	5.23M	128.6M	3.41M	-220K
Change in Inventory	-5.88M	-6.61M	-3.54M	4.59M	-12.13M	-77.64M	30.68M	13.66M	15.2M	4.22M
Change in Payables	-18.12M	-19.82M	20.17M	-26.08M	15.64M	37.16M	-10.85M	-9.39M	2.83M	-20.66M
Cash from Investing+	-99.22M	-20.7M	-46.67M	-26.12M	-13.27M	-18.33M	35.95M	91.04M	-18.2M	352.21M
Capital Expenditures	-15.85M	-23.55M	-46.52M	-27.86M	-12.74M	-33.68M	-32.16M	-24.58M	-16.27M	-25.01M
CapEx % of Revenue	0.03%	0.02%	0.05%	0.03%	0.01%	0.02%	0.02%	0.02%	0.02%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-9.38M	1.4M	-39.25M	-26.64M	671K	245K	66.03M	1.95M	2.71M	210.62M
Cash from Financing+	33.01M	-35.2M	61.04M	140.91M	175.25M	-35.08M	-10.35M	22.97M	-11.3M	184.17M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	26.02M	8.58M	2.13M	1.17M	-7.76M	756K	893K	-774K	-272K	-13.59M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	148.18M	8.5M	-138.6M	-137M	-185.26M	5.79M	6.18M	-119.77M	-44.47M	-208.5M
FCF Margin %	0.3%	0.01%	-0.14%	-0.14%	-0.21%	0%	0%	-0.12%	-0.05%	-0.29%
FCF Growth %	2.56%	-0.94%	-17.31%	0.01%	-0.35%	1.03%	0.07%	-20.38%	0.63%	-3.69%
FCF per Share	0.30	0.02	-0.25	-0.24	-0.31	0.01	0.01	-0.17	-0.06	-0.30
FCF Conversion (FCF/Net Income)	-5.46x	-0.66x	0.30x	0.71x	0.55x	1.29x	-1.27x	0.29x	0.15x	3.45x
Interest Paid	4.57M	2.89M	1.31M	0	11.87M	10.91M	8.52M	7.42M	8.13M	20.88M
Taxes Paid	4.88M	27.12M	5.42M	0	2.67M	903K	5.97M	8.04M	3.71M	10.01M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2.14%	-2.38%	-15.51%	-8.42%	-18.49%	1.86%	-1.8%	-20.23%	-12.8%	-3.86%
Return on Invested Capital (ROIC)	-5.28%	-2.77%	-10.53%	-7.06%	-11.51%	2.32%	0.76%	-9.64%	-7.06%	-7.46%
Gross Margin	52.17%	49.95%	35.8%	38.95%	36.53%	37.69%	32.77%	28.7%	36.84%	43.61%
Net Margin	-6.11%	-3.96%	-31.6%	-15.45%	-34.92%	2.13%	-1.7%	-32.7%	-21.87%	-7.46%
Debt / Equity	0.08x	0.05x	0.09x	0.02x	0.20x	0.18x	0.15x	0.20x	0.24x	0.37x
Interest Coverage	-11.70x	-9.86x	-41.88x	-14.40x	-12.74x	2.63x	0.99x	-18.77x	-11.63x	-3.20x
FCF Conversion	-5.46x	-0.66x	0.30x	0.71x	0.55x	1.29x	-1.27x	0.29x	0.15x	3.45x
Revenue Growth	439.74%	148.46%	-20.93%	2.51%	-8.92%	59.15%	23.64%	-43.42%	-14.01%	-17.41%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Service	-	-	-	813.25M	716.43M	1.26B	1.61B	755.63M	515.27M	480.67M
Service Growth	-	-	-	-	-11.90%	76.18%	27.32%	-52.98%	-31.81%	-6.72%
Product	-	-	-	107.11M	-	119.95M	141.77M	142.84M	167.56M	155.11M
Product Growth	-	-	-	-	-	-	18.19%	0.76%	17.30%	-7.43%
Transfer of Intellectual Property and Other	-	-	-	-	-	-	25.84M	105.72M	180.66M	77.36M
Transfer of Intellectual Property and Other Growth	-	-	-	-	-	-	-	309.11%	70.89%	-57.18%
Client Payers	-	-	-	150.26M	159.97M	637.64M	-	-	-	-
Client Payers Growth	-	-	-	-	6.46%	298.60%	-	-	-	-
Health Insurers	-	-	-	370.1M	419.1M	483.64M	-	-	-	-
Health Insurers Growth	-	-	-	-	13.24%	15.40%	-	-	-	-
Government Payers	-	-	-	271.59M	116.66M	90.29M	-	-	-	-
Government Payers Growth	-	-	-	-	-57.04%	-22.61%	-	-	-	-
Rayaldee	-	1.6M	21.58M	36.72M	-	88.19M	-	-	-	-
Rayaldee Growth	-	-	1248.88%	70.12%	-	-	-	-	-	-
Patients	-	-	-	21.3M	20.7M	50.67M	-	-	-	-
Patients Growth	-	-	-	-	-2.84%	144.78%	-	-	-	-
Transfer Of Intellectual Property And Other	-	-	-	69.91M	-	28.7M	-	-	-	-
Transfer Of Intellectual Property And Other Growth	-	-	-	-	-	-	-	-	-	-
Diagnostics	329.6M	-	-	-	-	-	-	-	-	-
Diagnostics Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	344.46M	1.01B	908.97M	837.51M	751.1M	1.32B	1.64B	783.21M	597.82M	546.3M
UNITED STATES Growth	-	194.48%	-10.39%	-7.86%	-10.32%	75.45%	24.48%	-52.25%	-23.67%	-8.62%
CHILE	29.89M	35.36M	44.29M	41.22M	33.64M	44.15M	63.8M	62.04M	68.49M	65.05M
CHILE Growth	-	18.33%	25.23%	-6.93%	-18.38%	31.24%	44.49%	-2.75%	10.39%	-5.03%
IRELAND	78.99M	137.78M	77.28M	78.1M	81.17M	43.92M	32.81M	117.21M	141.47M	48.4M
IRELAND Growth	-	74.44%	-43.91%	1.06%	3.93%	-45.89%	-25.30%	257.26%	20.69%	-65.79%
SPAIN	16.62M	15.81M	18.29M	18.2M	18.75M	16.93M	22.68M	22.48M	23.52M	24.63M
SPAIN Growth	-	-4.87%	15.64%	-0.49%	3.03%	-9.68%	33.96%	-0.90%	4.63%	4.75%
MEXICO	3.67M	2.99M	4.61M	5.6M	8.03M	7.87M	11.01M	14.55M	20.22M	23.87M
MEXICO Growth	-	-18.61%	54.12%	21.56%	43.48%	-2.08%	39.92%	32.18%	38.98%	18.06%
Other Countries	-	6K	120K	167K	476K	526K	507K	863K	2.25M	3.12M
Other Countries Growth	-	-	1900.00%	39.17%	185.03%	10.50%	-3.61%	70.22%	160.25%	39.05%
ISRAEL	18.11M	15.32M	13.95M	9.48M	8.77M	4.25M	3.56M	3.85M	9.74M	1.77M
ISRAEL Growth	-	-15.41%	-8.92%	-32.06%	-7.49%	-51.52%	-16.18%	7.91%	153.26%	-81.80%

Frequently Asked Questions

Growth & Financials

OPKO Health, Inc. (OPK) reported $642.1M in revenue for fiscal year 2024. This represents a 2195% increase from $28.0M in 2011.

OPKO Health, Inc. (OPK) saw revenue decline by 17.4% over the past year.

OPKO Health, Inc. (OPK) reported a net loss of $140.8M for fiscal year 2024.

Dividend & Returns

OPKO Health, Inc. (OPK) has a return on equity (ROE) of -3.9%. Negative ROE indicates the company is unprofitable.

OPKO Health, Inc. (OPK) had negative free cash flow of $212.1M in fiscal year 2024, likely due to heavy capital investments.